Comparative efficacy of topical oclacitinib 0.1% and tacrolimus 0.01% in canine keratoconjunctivitis sicca.
Juliana Kravetz de OliveiraDavid L WilliamsCamila BollmannNathália Mendonça de SeabraMariza BortoliniFabiano Montiani-FerreiraPublished in: Veterinary ophthalmology (2019)
Topical 0.1% oclacitinib twice daily is not effective in controlling the ocular signs of KCS in dogs. 0.01% tacrolimus increased STT-1 values significantly and could potentially be used as a treatment for mild-to-moderate cases of KCS. Synergism between drugs did not occur, and therefore the use of oclacitinib is not justified in cases of canine KCS.